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Summary  An  enormous  amount  of  molecular  and  phenotypic  information  of  drugs  as  well
as diseases  is  now  available  in  public  repositories.  Computational  analysis  of  these  datasets
is facilitating  the  acquisition  of  a  systems  view  of  how  drugs  act  on  our  human  organism  and
interfere with  diseases.  Here,  I highlight  recent  approaches  integrating  large-scale  informationprediction;
Drug—disease
connections;
Computational
approaches;
of drugs  and  diseases  that  are  contributing  to  change  our  current  view  on  how  drugs  interfere
with human  diseases.
© 2016  Beilstein-lnstitut.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the
CC BY-NC-ND  license  (http://creativecommons.org/licenses/by/4.0/).
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IntroductionSmall  molecules  are  the  substances  most  often  used  as
therapeutic  agents.  However,  despite  the  huge  investment
of  pharmaceutical  companies  in  the  development  of  new
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(http://creativecommons.org/licenses/by/4.0/).rugs,  only  few  novel  compounds  are  approved  annually  for
edical  treatment  (Emanuel,  2015).  The  high  drug  attrition
ate  is  due  to  a  lack  of  efﬁcacy  and  unexpected  toxicity  of
rugs  (Waring  et  al.,  2015),  indicating  that  our  understand-
ng  on  how  compounds  affect  human  biological  circuits  and
nterfere  with  diseases  is  far  from  complete.
The  recent  explosion  of  biological  information  of  drugs
n  the  public  domain  is  facilitating  the  study  of  drug  action
n  the  human  organism  in  an  unprecedented  scale.  Over
he  last  two  decades,  several  databases  storing  molecu-
ar  and  phenotypic  information  of  drugs  have  appeared  on
he  public  domain.  Examples  of  drug  target  databases  are
rugBank  (Wishart  et  al.,  2006),  ChEMBL  (Gaulton  et  al.,
011) and  Matador  (Gunther  et  al.,  2008).  Repositories  of
n  vivo  and  in  vivo  phenotypic  effects  of  drugs  include  SIDER
Kuhn  et  al.,  2010,  2016),  a  database  of  side  effects  of
arketed  drugs,  warehouses  of  high-throughput  chemical
his is an open access article under the CC BY-NC-ND license
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Figure  1  The  classical  pharmacology  view  of  ‘‘one  drug,  one  target,  one  disease’’  (A)  is  changing  to  a  more  complex  scenario  of
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s‘many drugs,  many  targets  and  many  diseases’’  (B).
enetics  experiments  such  as  ChemBank  (Seiler  et  al.,  2008)
nd  PubChem  Biassay  (Wang  et  al.,  2009)  and  repositories  of
ene  expression  proﬁles  after  drug  perturbation  in  cancer
ell  lines  (Lamb  et  al.,  2006).
Resources  containing  large-scale  information  of  diseases
ave  existed  since  more  than  three  decades.  The  ﬁrst
atabase  collecting  clinical  as  well  as  molecular  information
f  inherited  diseases  was  the  ‘Online  Mendelian  Inheritance
n  Man  (OMIM)’  (http://omim.org/).  More  recently,  dedi-
ated  databases  storing  genome-wide  association  disease
tudies  (GWAS),  such  as  the  NHGRI  GWAS  Catalog  (Welter
t  al.,  2014)  and  molecular  information  of  diseases  (Pinero
t  al.,  2015)  as  well  as  resources  offering  clinical  phenotypes
f  more  than  5000  common  and  rare  diseases  (Kohler  et  al.,
014;  Vogt  et  al.,  2014a,b)  such  as  Orphanet  and  Decipher
Firth  et  al.,  2009)  have  been  released  in  the  public  domain.
The  integrative  analysis  of  chemical  and  disease  infor-
ation  is  changing  our  view  on  drug  mechanisms  of  action
s  well  as  how  drugs  interfere  with  disease  mechanisms.
he  analysis  of  large-scale  drug  target  information  soon
videnced  the  polypharmacological  activity  of  drugs,  that  is,
he  property  of  drugs  to  interfere  with  many  protein  targets
Anighoro  et  al.,  2014;  Jalencas  and  Mestres,  2013;  Peters,
013).  The  classical  view  of  ‘‘one  drug,  one  target,  one  dis-
ase’’  (Imming  et  al.,  2006)  is  evolving  to  a  more  complex
cenario  of  ‘‘many  drugs,  many  targets  and  many  diseases’’
Mestres  et  al.,  2008;  Yildirim  et  al.,  2007)  (Fig.  1).  Here, will  highlight  recent  computational  efforts  that  have  con-
ributed  to  enhance  our  knowledge  of  drug  modes  of  action
nd  disease  relationships.
m
tesults
lucidation  of  drug  targets
ue  to  the  medical  and  biological  relevance  of  the  discovery
f  novel  drug  targets,  uncovering  new  targets  of  drugs  has
een  an  active  area  on  drug  discovery  research  in  the  last
ears.  Diverse  chemo  and  bio-informatics  approaches  have
een  developed  to  predict  drug  targets.  Chemo-informatics
pproaches  exploit  similarities  on  two  and  three  dimen-
ional  structural  features  of  compounds  to  assign  novel
argets  to  compounds  (Keiser  et  al.,  2007;  Liu  et  al.,
013;  Paolini  et  al.,  2006;  Xia  et  al.,  2004),  while  bio-
nformatics  approaches  rely  on  the  analysis  of  biological
roperties  of  drugs.  These  properties  include  side  effects
Campillos  et  al.,  2008),  gene  expression  proﬁles  after
rug  perturbation  (Lamb  et  al.,  2006;  Xia  et  al.,  2004),
ytotoxicity  proﬁles  of  chemicals  across  a  panel  of  can-
er  cell  lines  (Shoemaker,  2006) and  bioactivity  proﬁles  of
hemicals  on  chemical  genetics  screens  (Petrone  et  al.,
012).
Biological  and  chemical  properties  of  compounds  have
lso  been  exploited  in  combination  to  uncover  molecu-
ar  information  of  compounds,  for  example  in  docking
pproaches  where  the  interaction  between  compounds  and
roteins  are  modeled  based  on  the  compound  and  protein
tructures  (Laird  and  Blake,  2004)  and  machine-learning
ethods  that  incorporate  chemical  structure  and  protein
arget  information  (Li  et  al.,  2015).
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Drug—disease  relationships
Recent  computational  approaches  exploit  large  scale  infor-
mation  on  drugs  and  diseases  to  infer  novel  drug—disease
connections  (Guney  et  al.,  2016;  Vogt  et  al.,  2014a;  Hopkins
and  Groom,  2002;  Yildirim  et  al.,  2007).  Proﬁling  meth-
ods  where  signatures  of  phenotypic  features  such  as  gene
expression  proﬁles  of  drugs  and  diseases  are  compared  is  a
common  approach  to  link  drugs  and  diseases.  In  this  context,
anticorrelations  of  gene  expression  proﬁles  after  drug  per-
turbation  in  cancer  cell  lines  with  gene  expression  signatures
of  diseases  have  revealed  novel  drug—disease  connections
(Lamb  et  al.,  2006).
Recently,  a  semantic  similarity  method  comparing  signa-
tures  of  organismal  phenotypes  of  drugs  and  diseases  has
shown  that  drug—disease  pairs  sharing  organismal  pheno-
types  are  often  molecularly  as  well  as  clinically  related  (Vogt
et  al.,  2014a),  that  is,  phenotypically  similar  drug—disease
pairs  are  enriched  in  drugs  whose  protein  targets  are  func-
tionally  related  to  proteins  encoded  in  disease  genes.  In
addition,  in  these  pairs,  the  drug  is  often  indicated  or
contraindicated  for  the  disease.  Interestingly,  we  found
that  contraindicated  drug—disease  pairs  are  preferentially
enriched  in  molecularly  related  associations,  suggesting  that
by  targeting  the  protein  causally  related  to  the  disease,  the
drug  can  cause  the  disease  and  thereby  produce  side  effects
resembling  disease  symptoms.  This  ﬁnding  was  exploited
to  propose  drug  contraindications  based  on  the  phenotypic
similarity  of  drugs  and  diseases.
Another  rich  source  of  drug—disease  associations  are
chemical  screens  where  the  activity  of  a  library  of  small
molecules  is  tested  in  phenotypic  assays  modeling  diseases.
Methods  that  combine  phenotypic  high-throughput  chemical
screens  stored  in  public  repositories  with  predicted  protein
targets  of  compounds  have  proven  useful  to  uncover  not
only  drug  molecular  mechanisms  responsible  for  the  phe-
notypic  activity  of  compounds  in  chemical  screens  disease
relationships  but  also  drug—disease  relationships  (Liu  and
Campillos,  2014;  Petrone  et  al.,  2012;  Wassermann  et  al.,
2015).  High-throughput  chemical  screening  in  cancer  cell
lines  is  opening  novel  opportunities  for  the  discovery  of
personalized  treatments  in  cancer.  Computational  analyses
exploiting  cell  cytotoxicity  information  of  thousands  of  small
molecules  and  an  extensive  molecular  information  of  cell
lines  such  as  gene  mutations  and  transcriptomics  informa-
tion  are  uncovering  molecular  biomarkers  of  drug  sensitivity
as  well  as  drug  mechanism  of  actions  (Garnett  et  al.,  2012;
Rees  et  al.,  2016;  Shoemaker,  2006).
Methods  that  analyze  drug—disease  connections  using
molecular  networks  have  contributed  to  obtain  a  systems
view  of  drug  therapeutic  action  (Yildirim  et  al.,  2007).  These
analyses  have  revealed  that  only  a  small  number  of  drugs  tar-
get  disease  mechanisms  directly,  implying  that  the  majority
of  drugs  have  a  palliative  effect,  treating  disease  symptoms
rather  than  disease  molecular  causes  (Guney  et  al.,  2016;
Vogt  et  al.,  2014a;  Yildirim  et  al.,  2007).
Concluding  remarksThe  studies  mentioned  above  illustrate  the  possibilities  of
integrative  computational  methods  for  the  discovery  of
novel  insights  of  drugs  and  diseases.  It  is  envisioned  thatecules  in  diseases  51
he  upcoming  clinical  and  molecular  information  of  patients
ncluding  individual  genome  sequences  and  epigenomes,
etailed  clinical  information  on  patients,  histopathologi-
al  features  and  even  single-cell  information  will  open  new
venues  for  a  deeper  understanding  of  the  individual  drug
esponse.  The  analysis  of  this  amount  of  information  will
ertainly  require  advanced  methods  crossing  the  bioinfor-
atics,  system  biology  and  systems  medicine  disciplines  to
recisely  determine  the  best  individual  treatment  option.
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